Report cover image

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Aug 30, 2022
Length 56 Pages
SKU # GMD17396375

Description

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Matrix Metalloproteinase 9 - Drugs In Development, 2022, outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Dermatology, Gastrointestinal, Cardiovascular, Immunology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Infectious Disease, Metabolic Disorders and Undisclosed which include indications Epilepsy, Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Wounds, Acute Ischemic Stroke, Amyotrophic Lateral Sclerosis, Atopic Dermatitis (Atopic Eczema), Burns, Cancer Pain, Chemotherapy Induced Pain, Crohn's Disease (Regional Enteritis), Diabetic Neuropathy, Dupuytren Contracture, Fibrosis, Genital Herpes, Herpes Labialis (Oral Herpes), Herpes Zoster (Shingles), Herpetic Keratitis, Inflammation, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Liver Fibrosis, Melanoma, Metastatic Cancer, Metastatic Melanoma, Myocardial Infarction, Ocular Pain (Eye Pain), Opium (Opioid) Addiction, Pancreatic Islet Transplant Rejection, Pulmonary Fibrosis, Pulmonary Inflammation, Simplexvirus (HSV) Infections, Spinal Cord Injury and Unspecified.

Furthermore, this report also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

56 Pages
Introduction
Global Markets Direct Report Coverage
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Overview
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Companies Involved in Therapeutics Development
Accure Therapeutics SL
Aquilus Pharmaceuticals Inc
AstraZeneca Plc
EA Pharma Co Ltd
Elastomics AB
Iproteos SL
MabTrix Ltd
Pharmahungary Group
Pikralida Sp zoo
Proteris Biotech Inc
Releviate Therapeutics
Shulov Innovative Science Ltd
Translational Sciences Inc
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Drug Profiles
ACT-03 – Drug Profile
AQU-010 – Drug Profile
AQU-118 – Drug Profile
AZD-1236 – Drug Profile
CALY-001 – Drug Profile
IPRO-003 – Drug Profile
M-9i – Drug Profile
Monoclonal Antibody to Inhibit MMP9 for Inflammatory Bowel Disease – Drug Profile
ND-336 – Drug Profile
PKL-021 – Drug Profile
Protearin – Drug Profile
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection – Drug Profile
Recombinant Protein to Target MMP-9 for Wounds – Drug Profile
RLVT-903 – Drug Profile
Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology – Drug Profile
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma – Drug Profile
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction – Drug Profile
Vaccine to Target MMP2 and MMP9 for Melanoma – Drug Profile
ZEP-3 – Drug Profile
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Dormant Products
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Discontinued Products
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) – Product Development Milestones
Featured News & Press Releases
May 20, 2022: Birmingham research brings hope for spinal cord injury treatment
Jul 12, 2021: Co-financing from 3/1.1.1/2020 fast track for Mazovia competition
Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indications, 2022
Table 4: Number of Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Number of Products under Investigation by Universities/Institutes, 2022
Table 8: Products under Investigation by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Mechanism of Actions, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Pipeline by Accure Therapeutics SL, 2022
Table 13: Pipeline by Aquilus Pharmaceuticals Inc, 2022
Table 14: Pipeline by AstraZeneca Plc, 2022
Table 15: Pipeline by EA Pharma Co Ltd, 2022
Table 16: Pipeline by Elastomics AB, 2022
Table 17: Pipeline by Iproteos SL, 2022
Table 18: Pipeline by MabTrix Ltd, 2022
Table 19: Pipeline by Pharmahungary Group, 2022
Table 20: Pipeline by Pikralida Sp zoo, 2022
Table 21: Pipeline by Proteris Biotech Inc, 2022
Table 22: Pipeline by Releviate Therapeutics, 2022
Table 23: Pipeline by Shulov Innovative Science Ltd, 2022
Table 24: Pipeline by Translational Sciences Inc, 2022
Table 25: Dormant Products, 2022
Table 26: Dormant Products, 2022 (Contd..1)
Table 27: Dormant Products, 2022 (Contd..2)
Table 28: Dormant Products, 2022 (Contd..3)
Table 29: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Routes of Administration, 2022
Figure 6: Number of Products by Stage and Routes of Administration, 2022
Figure 7: Number of Products by Molecule Types, 2022
Figure 8: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us